Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pem...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho‐ichi Yamagishi, Yusaku Mori
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Wiley 2023-12-01
Reeks:	Journal of Diabetes Investigation
Onderwerpen:	Pemafibrates Small dense low‐density lipoprotein Type 2 diabetes
Online toegang:	https://doi.org/10.1111/jdi.14076

Gelijkaardige items

Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
door: Rino Okada, et al.
Gepubliceerd in: (2024-12-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
door: Junko Oya, et al.
Gepubliceerd in: (2023-11-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
door: Masahiro Kikuchi, et al.
Gepubliceerd in: (2024-09-01)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
door: Hiroshi Nomoto, et al.
Gepubliceerd in: (2023-06-01)

Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
door: Aki Okamoto, et al.
Gepubliceerd in: (2025-02-01)

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
door: Deokho Lee, et al.
Gepubliceerd in: (2023-01-01)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
door: Hiroshi Nomoto, et al.
Gepubliceerd in: (2023-10-01)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
door: Shigeki Kitamura, et al.
Gepubliceerd in: (2023-09-01)

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD
door: Takanobu Iwadare, et al.
Gepubliceerd in: (2024-05-01)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
door: Shizuya Yamashita, et al.
Gepubliceerd in: (2023-05-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
door: Ryosuke Sugimoto, et al.
Gepubliceerd in: (2023-02-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
door: Takeshi Hatanaka, et al.
Gepubliceerd in: (2021-10-01)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
door: Naofumi Amioka, et al.
Gepubliceerd in: (2022-06-01)

Lessons from PROMINENT and prospects for pemafibrate
door: Jean-Charles Fruchart, et al.
Gepubliceerd in: (2024-07-01)

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
door: Kazufumi Dohmen, et al.
Gepubliceerd in: (2021-10-01)

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
door: Yasutaka Takeda, et al.
Gepubliceerd in: (2023-03-01)

The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
door: Yasutaka Takeda, et al.
Gepubliceerd in: (2023-01-01)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
door: Suguru Ikeda, et al.
Gepubliceerd in: (2021-12-01)

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
door: Daiki Aomura, et al.
Gepubliceerd in: (2021-06-01)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
door: Zhe Zhang, et al.
Gepubliceerd in: (2022-07-01)

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect
door: Azuma Watanabe, et al.
Gepubliceerd in: (2023-10-01)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
door: Takanobu Iwadare, et al.
Gepubliceerd in: (2022-11-01)

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score
door: Takeshi Ichikawa, et al.
Gepubliceerd in: (2023-12-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
door: Satoshi Shinozaki, et al.
Gepubliceerd in: (2025-02-01)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
door: Hidekatsu Yanai, et al.
Gepubliceerd in: (2022-02-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
door: Hiroki Ono, et al.
Gepubliceerd in: (2024-04-01)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
door: Yusaku Mori, et al.
Gepubliceerd in: (2019-10-01)

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
door: Satoshi Shinozaki, et al.
Gepubliceerd in: (2023-06-01)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
door: Hideki Kushima, et al.
Gepubliceerd in: (2017-10-01)

Effect of statin add-on therapy on cardiovascular mortality
door: John R. Nelson, et al.
Gepubliceerd in: (2024-03-01)

Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus
door: Hironori Yashima, et al.
Gepubliceerd in: (2019-03-01)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
door: Feher M, et al.
Gepubliceerd in: (2013-01-01)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
door: Nobuaki Takehana, et al.
Gepubliceerd in: (2023-07-01)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
door: Shotaro Kamata, et al.
Gepubliceerd in: (2023-08-01)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
door: Michishige Terasaki, et al.
Gepubliceerd in: (2021-07-01)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
door: Michishige Terasaki, et al.
Gepubliceerd in: (2017-01-01)

Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
door: G. S. Mal’
Gepubliceerd in: (2005-06-01)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
door: Michishige Terasaki, et al.
Gepubliceerd in: (2015-01-01)

Analysis of serum levels and DNA methylation of fibroblast growth factor 21 using peripheral blood-derived genomes in patients with obesity
door: Hiroyuki Shinozaki, et al.
Gepubliceerd in: (2024-09-01)

No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
door: Tsutomu Hirano
Gepubliceerd in: (2023-04-01)